The Cannabis Science Conference, which took place August 28–29, 2018 in Portland, Oregon, saw another year of record-breaking attendance and exhibitors.
Cannabis Science and Technology magazine is seeking contributed manuscripts for the November 2018 and January 2019 issues.
The FDA released a statement this week about reports of severe illnesses and deaths resulting from the use of synthetic cannabinoid products that have been contaminated with brodifacoum.
The U.S. Food and Drug Administration (FDA) recently approved the drug Epidiolex, which contains cannabidiol (CBD), as an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy—Lennox-Gastaut syndrome and Dravet syndrome—in patients two years of age and older (1).
EVIO Labs Florida (Broward County, Florida) was recently recognized for their participation in The Emerald Test (Emerald Scientific), which is an interlaboratory comparison and proficiency assessment for cannabis testing.
Thomas Jefferson University Announces Initiative to Study Health Outcomes in Medical Cannabis Patients
On Monday, May 14, 2018, Pennsylvania became the first state to add opioid addiction to its list of approved conditions for medicinal cannabis.
The online news service NJ Spotlight hosted a half-day event on May 11, 2018, at the Hilton Garden Inn in Hamilton, New Jersey, titled “Marijuana Legalization in NJ: Understanding the Opportunity and Challenges.” The event was sponsored b
Mike James, a free agent with the National Football League (NFL) and former running back for the Tampa Bay Buccaneers and the Detroit Lions, is the first NFL athlete to apply for a therapeutic use exemption (TUE) for cannabis.
Steep Hill, the global leader in cannabis science, genetics, research, testing, and analytics headquartered in Berkeley, California, announced plans this week to expand into the global cannabis market.